ZA200106849B - Heteroaryl amidines, methylamidines and guanidines as protease inhibitors. - Google Patents

Heteroaryl amidines, methylamidines and guanidines as protease inhibitors. Download PDF

Info

Publication number
ZA200106849B
ZA200106849B ZA200106849A ZA200106849A ZA200106849B ZA 200106849 B ZA200106849 B ZA 200106849B ZA 200106849 A ZA200106849 A ZA 200106849A ZA 200106849 A ZA200106849 A ZA 200106849A ZA 200106849 B ZA200106849 B ZA 200106849B
Authority
ZA
South Africa
Prior art keywords
carboxamidine
amino
methylthiothiophene
methylthio
thiophene
Prior art date
Application number
ZA200106849A
Other languages
English (en)
Inventor
Carl R Illig
Nalin L Subasinghe
James B Hoffman
Kenneth J Wilson
M Jonathan Rudolph
Juan Jose Marugan
Original Assignee
Dimensional Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimensional Pharm Inc filed Critical Dimensional Pharm Inc
Publication of ZA200106849B publication Critical patent/ZA200106849B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
ZA200106849A 1999-02-09 2001-08-20 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors. ZA200106849B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24706299A 1999-02-09 1999-02-09

Publications (1)

Publication Number Publication Date
ZA200106849B true ZA200106849B (en) 2002-11-20

Family

ID=22933398

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200106849A ZA200106849B (en) 1999-02-09 2001-08-20 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors.

Country Status (19)

Country Link
EP (1) EP1150979A1 (hu)
JP (1) JP2002536446A (hu)
KR (1) KR20010098982A (hu)
CN (1) CN1337961A (hu)
AU (1) AU5671799A (hu)
BG (1) BG105866A (hu)
BR (1) BR9917036A (hu)
CA (1) CA2362390A1 (hu)
CZ (1) CZ20012858A3 (hu)
EA (1) EA200100882A1 (hu)
HU (1) HUP0201475A2 (hu)
IL (1) IL144560A0 (hu)
MX (1) MXPA01008084A (hu)
NO (1) NO324887B1 (hu)
NZ (1) NZ513701A (hu)
PL (1) PL351767A1 (hu)
SK (1) SK11422001A3 (hu)
WO (1) WO2000047578A1 (hu)
ZA (1) ZA200106849B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047194A2 (en) * 1999-02-09 2000-08-17 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
BR0311419A (pt) * 2002-05-28 2005-04-05 Dimensional Pharm Inc Amidinas de tiofeno suas composições e métodos de tratamento de doenças e condições mediadas por complemento
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
JP2007523868A (ja) * 2003-07-10 2007-08-23 アキリオン ファーマシューティカルズ,インコーポレーテッド ウイルス複製の阻害薬として有用な置換アリールチオウレア誘導体類
CA2555959A1 (en) 2004-02-12 2005-09-01 Molecular Insight Pharmaceuticals Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof
US8841305B2 (en) 2008-10-09 2014-09-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of the human pyruvate kinase M2 receptor
WO2011005660A1 (en) 2009-07-08 2011-01-13 Valocor Therapeutics, Inc. Tofa analogs useful in treating dermatological disorders or conditions
EP2563761A1 (en) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
US8691184B2 (en) * 2011-01-25 2014-04-08 The Regents Of The University Of Michigan Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
AR086744A1 (es) * 2011-06-28 2014-01-22 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
EP2606726A1 (de) * 2011-12-21 2013-06-26 Bayer CropScience AG N-Arylamidine-substituierte trifluoroethylsulfid-Derivate als Akarizide und Insektizide
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Flap調節劑
EP3495359A1 (en) 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap modulators
BR112020019804A2 (pt) * 2018-03-30 2021-01-05 Sumitomo Chemical Company, Limited Composto heterocíclico e composição de controle de peste artrópode contendo o mesmo
CN109020837A (zh) * 2018-07-27 2018-12-18 广东省石油与精细化工研究院 一种2-取代苯基-乙脒盐酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220654A (en) * 1979-06-04 1980-09-02 Merck & Co., Inc. Cyclic imidazole cyanoguanidines
US4424367A (en) * 1982-08-19 1984-01-03 Norwich Eaton Pharmaceuticals, Inc. 5-(4-Aminophenyl)-2-thiophenecarboximidamide hydrochloride hemihydrate
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
DE3427865A1 (de) * 1984-07-27 1986-02-06 Torii & Co., Tokio/Tokyo Amidinoverbindungen, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
GB9312761D0 (en) * 1993-06-21 1993-08-04 Wellcome Found Amino acid derivatives
CA2170735A1 (en) * 1993-10-21 1995-04-27 Foe S. Tjoeng Amidino derivatives useful as nitric oxide synthase inhibitors
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
TW414795B (en) * 1996-07-01 2000-12-11 Yamanouchi Pharma Co Ltd A thiophene derivative and the pharmaceutical composition
DE19632773A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
EP1051431A1 (de) * 1998-01-26 2000-11-15 Basf Aktiengesellschaft Thrombininhibitoren
EP1049673A1 (de) * 1998-01-26 2000-11-08 Basf Aktiengesellschaft Heterocyclische amidine als kallikrein protease inhibitoren
ATE223408T1 (de) * 1998-02-09 2002-09-15 Dimensional Pharm Inc Heteroaryl-amidinen,-methylamidinen und - guanidinen als protease inhibitoren, insbesondere als urokinase inhibitoren
EP1068190A1 (en) * 1998-03-31 2001-01-17 Warner-Lambert Company Llc Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
KR20010042296A (ko) * 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세린 프로테아제 억제제로서의 벤즈옥사지논/벤조티아지논
CA2312953A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors

Also Published As

Publication number Publication date
BR9917036A (pt) 2002-07-30
SK11422001A3 (sk) 2002-04-04
NO324887B1 (no) 2007-12-27
WO2000047578A1 (en) 2000-08-17
MXPA01008084A (es) 2004-09-10
AU5671799A (en) 2000-08-29
EA200100882A1 (ru) 2002-04-25
JP2002536446A (ja) 2002-10-29
CZ20012858A3 (cs) 2002-05-15
KR20010098982A (ko) 2001-11-08
NO20013853L (no) 2001-10-09
EP1150979A1 (en) 2001-11-07
CA2362390A1 (en) 2000-08-17
NZ513701A (en) 2001-09-28
CN1337961A (zh) 2002-02-27
IL144560A0 (en) 2002-05-23
NO20013853D0 (no) 2001-08-07
HUP0201475A2 (hu) 2003-10-28
BG105866A (en) 2002-06-28
PL351767A1 (en) 2003-06-16

Similar Documents

Publication Publication Date Title
US6562840B1 (en) Heteroaryl amidines, methylamidines and guanidines, and the use thereof as protease inhibitors
ZA200106849B (en) Heteroaryl amidines, methylamidines and guanidines as protease inhibitors.
EP1054886B1 (en) Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
US6492403B1 (en) Methods of treating C1s-mediated diseases and conditions and compositions thereof
CN100488947C (zh) 丝氨酸蛋白酶抑制剂
EP1680431A1 (en) Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
KR0173034B1 (ko) 선택적 트롬빈 억제제
WO1998055471A1 (en) Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
CA2443600A1 (en) Heterocyclyldicarbamides as caspase inhibitors
IL205242A (en) Transduced oxazolidinones and their use in the field of blood clotting
KR101179840B1 (ko) 치환 또는 무치환 아미노기를 도입한 4-피리딜알킬티오기를갖는 신규 고리형 화합물
JP2001521504A (ja) メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用
JP2002502852A5 (hu)
JP2002538136A (ja) アルケニルおよびアルキニル含有メタロプロテアーゼ阻害剤
JPH07196496A (ja) トロンボモジュリン発現を増大するための医薬組成物
JP2006096739A (ja) 置換又は無置換アミノ基を導入した4−ピリジルアルキルチオ基を有する新規環式化合物
JP2022524049A (ja) カスパーゼ阻害剤及びその使用方法
ES2209987T3 (es) Inhibidores de serina-proteasas de azacicloalcanona.
ZA200305262B (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cyssteine proteases.
EP1066272A1 (en) Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
KR19980076024A (ko) 경구투여가 가능한 선택적 트롬빈 억제제
ZA200209153B (en) Serine protease inhibitors.
KR19980075902A (ko) 경구투여가 가능한 선택적 트롬빈 억제제